TRVITrevi Therapeutics, Inc.vs its industry peers
A metric-by-metric comparison of Trevi Therapeutics, Inc. against SIC 2834 — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| Company | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TRVIThis | $2.0B#8 | — | 6.1x#8 | — | — | 10.7%#6 | — | -13.3%#3 | — | — | 29.6%#5 | — |
| XNCR | $2.3B#1 | — | 4.5x#5 | 18.2x#5 | 13.7%#9 | 60.5%#2 | -141.4%#7 | -18.3%#4 | -31.5%#4 | — | 120.4%#1 | — |
| VERA | $2.2B#2 | — | 5.4x#7 | — | — | -96.9%#8 | — | -73.5%#10 | -72.7%#5 | — | 18.5%#6 | — |
| PVLA | $2.2B#3 | — | 10.2x#10 | 51.6x#9 | 65.3%#4 | -139.3%#10 | -90.2%#6 | -19.2%#5 | — | — | 99.0%#3 | — |
| PRGO | $2.2B#4 | — | 0.9x#1 | 0.5x#1 | -2.8%#11 | -729.7%#14 | -26.4%#3 | -56.7%#9 | -20.9%#3 | 4#1 | -18.0%#8 | 7.3%#1 |
| HRMY | $2.2B#5 | 12.0x#1 | 2.2x#4 | 2.5x#3 | 21.5%#8 | 9.1%#7 | 24.0%#1 | 15.9%#1 | 25.5%#1 | 4#1 | — | — |
| ZYME | $2.1B#6 | — | 26.6x#12 | 20.2x#6 | 38.9%#7 | 33.9%#3 | -87.3%#5 | -100.9%#11 | — | — | 59.5%#4 | — |
| SEPN | $2.0B#7 | — | 5.3x#6 | 44.4x#8 | 4174.5%#1 | 31.9%#4 | -148.6%#8 | -12.6%#2 | — | — | 118.1%#2 | — |
| SRPT | $2.0B#9 | — | 1.3x#2 | 1.1x#2 | 4.3%#10 | -403.3%#13 | -37.5%#4 | -46.7%#8 | -73.0%#6 | — | -24.2%#9 | — |
| BRVE | $1.9B#10 | — | — | — | — | — | — | — | — | — | — | — |
| XERS | $1.9B#11 | — | — | 6.5x#4 | 43.7%#6 | 101.0%#1 | 8.5%#2 | — | 20.6%#2 | — | 4.6%#7 | — |
| PGEN | $1.9B#12 | — | 43.1x#13 | 194.1x#11 | 146.7%#2 | -98.6%#9 | -1141.1%#10 | -575.1%#13 | -91.2%#7 | — | — | — |
| AGIO | $1.9B#13 | — | 1.8x#3 | 34.5x#7 | 48.0%#5 | -161.3%#12 | -873.9%#9 | -40.3%#7 | — | — | — | — |
| ZBIO | $1.8B#14 | — | 7.5x#9 | 184.9x#10 | 100.0%#3 | -140.6%#11 | -3830.6%#11 | -152.9%#12 | -296.6%#8 | — | — | — |
| SLS | $1.8B#15 | — | 13.0x#11 | — | -100.0%#12 | 13.0%#5 | — | -19.5%#6 | — | — | — | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2834). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Some peers are still being computed, so this table covers part of the group and ranks are within the rows shown; it fills in shortly. This table timed out mid-build, so it covers part of the group; ranks are within the rows shown and it fills in shortly. Table built 2026-11-04.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice